Sarepta Therapeutics
NasdaqGS:SRPT Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 45 Fair Values set on narratives written by author
WA
Consensus Narrative from 22 Analysts
Advancements In Gene Therapy Pipeline Will Strengthen Future Prospects
Key Takeaways Expanding SRP-9003 and development of new treatments could diversify revenue and drive future growth through accelerated approvals. Transitioning ELEVIDYS manufacturing could enhance efficiency and margins, while addressing new patient groups may expand market reach.
View narrativeUS$184.20
FV
42.3% undervalued intrinsic discount36.39%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
24 days ago author updated this narrative